Canaccord analyst Caitlin Cronin lowered the firm’s price target on Zimmer Biomet to $115 from $120 and keeps a Hold rating on the shares. The firm updated its model following news of EPR implementation challenges announced late last week, headwinds which it believes it can contain to 2024 but which could impact up to 1% of FY24 sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $110 from $112 at Wells Fargo
- Wolfe starts Zimmer Biomet at Peer Perform, sees $115-$130 fair value
- Zimmer Biomet initiated with a Peer Perform at Wolfe Research
- Zimmer Biomet guidance update an ‘unwelcome negative,’ says Truist
- Zimmer news to erase some of recent rally, says Citi